The global Vaccines Market is estimated to be valued at USD 54.50 billion in 2025 and is projected to reach USD 111.3 billion by 2035, registering a compound annual growth rate (CAGR) of 7.4% over the forecast period

Metric	Value
Market Size in 2025	USD 54.50 billion
Projected Market Size in 2035	USD 111.3 billion
CAGR (2025 to 2035)	7.4%

Country-Wise Outlook

Country	CAGR (2025 to 2035)
United States	6.7%

Country	CAGR (2025 to 2035)
United Kingdom	6.2%

Country	CAGR (2025 to 2035)
European Union	6.4%

Country	CAGR (2025 to 2035)
Japan	6.1%

Country	CAGR (2025 to 2035)
South Korea	6.6%

The Preventive Vaccines Market report segments the industry into By Vaccine Type (Live/Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, mRNA Vaccines, Other Vaccine Types), By Disease Type (Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Mumps, and Rubella (MMR), COVID-19, Other Disease Types), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America).

Snapshot img

Vaccines Market Size 2025-2029

The vaccines market size is forecast to increase by USD 160.22 billion at a CAGR of 23.1% between 2024 and 2029.

The market is experiencing significant growth, driven by increased funding for research and development, leading to the launch of new vaccines. One of the most promising trends in this market is the development of nanoparticle vaccines, which offer enhanced immunogenicity and improved delivery systems. This trend is particularly evident in the development of nanoparticle vaccines, which offer enhanced efficacy and safety. However, the high cost of research, development, and manufacturing poses a significant challenge for market players. Examples include the inactivated polio vaccine (IPV) and influenza vaccine. These costs can be attributed to the complex production processes involved in vaccine creation, as well as the need for rigorous clinical trials to ensure safety and efficacy. 
However, the high cost of vaccine research, development, and manufacturing remains a significant challenge for market participants. Despite this, the market presents numerous opportunities for companies seeking to capitalize on the growing demand for vaccines, particularly in emerging economies with rising healthcare expenditures. Strategic partnerships, collaborations, and acquisitions are key strategies for companies looking to navigate the competitive landscape and stay ahead of the curve.
Overall, the market is poised for continued growth, with significant opportunities for innovation and investment in the coming years. Companies that can effectively address the challenges of cost and regulatory compliance while delivering high-quality, effective vaccines will be well-positioned to succeed.

What will be the Size of the Vaccines Market during the forecast period?

Request Free Sample

The market driven by the continuous development of immunization programs and the pursuit of vaccine equity. Immunological memory, antibody response, and cost-effectiveness analysis are key factors influencing market growth. Vaccine supply chain, efficacy testing, preservation, patent, and licensing are essential aspects of the market. Nanotechnology and universal vaccines are emerging trends, aiming to improve vaccine accessibility and quality control. Vaccine manufacturing, regulatory approval, and economic impact are crucial elements in the market, with intellectual property, vaccine shelf life, and vaccine development pipeline being significant factors.
Vaccine innovation and vaccine safety monitoring are essential for addressing disease burden and ensuring potency, stability, and sterility. Vaccine logistics and vaccine stability are critical for successful distribution and administration, while vaccine safety monitoring emphasizes the importance of ongoing surveillance and immune response assessment. 

How is this Vaccines Industry segmented?

The vaccines industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Subunit vaccines
  Live attenuated vaccines
  Inactivated vaccines
  Toxoid vaccines
  Others


End-user

  Hospitals
  Clinics


Technology

  mRNA vaccines
  Viral vector vaccines
  Protein based vaccines
  DNA vaccines
  Others


Route Of Administration

  Intramuscular
  Subcutaneous
  Oral
  Intranasal
  Others


Disease Type

  Influenza
  Human papillomavirus
  Hepatitis
  Measles
  mumps
  rubella
  Others


Age Group

  Pediatric
  Adult
  Adolescent
  Geriatric


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

By Type Insights

The subunit vaccines segment is estimated to witness significant growth during the forecast period.

Subunit vaccines, integral components of the healthcare system's disease prevention strategy, employ specific antigenic pieces of a pathogen, such as proteins, sugars, or capsids, to induce a robust immune response. These vaccines, including the mRNA vaccines, are designed to target specific components of the pathogen, making them highly effective in preventing infections. The development process involves identifying and isolating these antigenic components, followed by formulation and rigorous testing to ensure safety and efficacy. For instance, in the realm of disease outbreak prevention, a phase 3 trial for the subunit TB vaccine candidate M72/AS01E was initiated in March 2024 in South Africa.

This trial aims to evaluate the vaccine's efficacy in preventing the progression from latent TB to active pulmonary TB, contributing to herd immunity and ultimately, disease surveillance and vaccine distribution within the healthcare s

The global vaccine market size was valued at USD 59.83 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 136.46 Billion by 2033, exhibiting a CAGR of 9.12% during 2025-2033. Asia-Pacific currently dominates the market, holding a significant market share of over 38.9% in 2024. The implementation of stringent regulations promoting vaccination adoption among individuals, several advances in biotechnology and vaccine development techniques, and growing health awareness among the population about the importance of vaccination are some of the major factors propelling the market.

Vaccines Market size is estimated to be valued at USD 81.91 Bn in 2025 and is expected to expand at a CAGR of 6.2%, reaching USD 124.88 Bn by 2032.

The U.S. vaccines market, currently exhibiting robust growth, is projected to maintain a significant upward trajectory throughout the forecast period (2025-2033). With a Compound Annual Growth Rate (CAGR) of 8.2%, the market's value, estimated at $XX billion in 2025, is expected to reach $YY billion by 2033 (Note: $XX and $YY billion are estimations based on the provided CAGR and assuming a consistent growth pattern; exact figures would require more specific market data). This expansion is fueled by several key drivers: increasing government initiatives promoting vaccination programs, rising prevalence of vaccine-preventable diseases, growing geriatric population requiring age-specific vaccines, and continuous advancements in vaccine technology, particularly in mRNA and viral vector platforms. The market's diverse segmentation, encompassing various vaccine types (live attenuated, mRNA, viral vectors, toxoid, others), routes of administration (parenteral, oral), disease indications (viral and bacterial diseases targeting specific age groups), and distribution channels (hospitals, retail pharmacies, government suppliers), presents lucrative opportunities for market players. Despite the positive outlook, several factors could restrain market growth. These include vaccine hesitancy and misinformation, stringent regulatory approvals for new vaccines, high research and development costs associated with novel vaccine development, and potential supply chain disruptions. However, the continuous efforts from public health organizations to educate the public on vaccination benefits, alongside ongoing innovations to improve vaccine efficacy, safety, and accessibility, are anticipated to mitigate these challenges. Key players like GSK, Sanofi, Pfizer, Merck, and Novartis, among others, are actively investing in research and development, strategic partnerships, and expansion strategies to solidify their market positions and capitalize on emerging trends within this dynamic and vital healthcare sector. The market's strong growth prospects are underpinned by the enduring importance of vaccines in public health and the commitment to improving global immunization coverage. Recent developments include: October 2023: Sanofi entered an agreement with Janssen Pharmaceuticals, Inc. to develop and commercialize a phase III vaccine product indicated against extraintestinal pathogenic E. coli., March 2023: CSL Limited established a new state-of-the-art vaccine R&D center in Massachusetts. The R&D facility is equipped with 54,000 square feet of lab space, comprising BSL-3 safety level., October 2022: GSK plc. received approval from the U.S. FDA for its vaccine, Menveo, with single vial presentation for individuals suffering from invasive meningococcal disease. The vaccine is intended for patients aged 10 years to 55 years.. Key drivers for this market are: Large Production of Products Coupled with New Approvals and Launches to Propel Market Growth. Potential restraints include: Long Production Cycle Coupled With High Cost of Production May Hinder Market Growth. Notable trends are: Shifting Preference toward mRNA-Based Products.

The global cancer vaccines market is estimated to reach a valuation of USD 11.29 billion in 2025. It is expected to reach USD 27.95 billion by 2035, reflecting a CAGR of 12% during the forecast period between 2025 and 2035.

Metrics	Values
Industry Size (2025E)	USD 11.29 billion
Industry Value (2035F)	USD 27.95 billion
CAGR	12%

The Pneumococcal Vaccines Market is estimated to be valued at USD 9.6 billion in 2025 and is projected to reach USD 14.4 billion by 2035, registering a compound annual growth rate (CAGR) of 4.1% over the forecast period.

Attribute	Detail
Market Size (2025)	USD 9.6 billion
Market Size (2035)	USD 14.4 billion
CAGR (2025 to 2035)	4.1%

The global veterinary vaccines market is projected to expand from USD 9.92 billion in 2025 to USD 16.34 billion by 2035, reflecting a CAGR of 5.2%.

Attributes	Key Insights
Estimated Size, 2025	USD 9.92 billion
Projected Size, 2035	USD 16.34 billion
Value-based CAGR (2025 to 2035)	5.2%

Country-wise Insights

Countries	Value CAGR (2025 to 2035)
USA	6.1%
China	7.9%
Germany	5.0%
UK	5.7%
Japan	4.5%
India	7.5%

Global Vaccines Market reached US$ 77.01 billion in 2024 and is expected to reach US$ 108.82 billion by 2032

The global pediatric vaccines market size reached USD 39.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 72.7 Billion by 2033, exhibiting a growth rate (CAGR) of 6.89% during 2025-2033. The growing conduction of vaccination programs, increasing focus on combination vaccines, and rising partnerships between pharmaceutical companies and healthcare organizations for fast-tracking the development and distribution of vaccines are some of the major factors propelling the market.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Historical Years	2019-2024
Market Size in 2024	USD 39.7 Billion
Market Forecast in 2033	USD 72.7 Billion
Market Growth Rate 2025-2033	6.89%

IMARC Group provides an analysis of the key trends in each segment of the global pediatric vaccines market report, along with forecasts at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on type, technology, and application.

• The global industry was valued at US$ 40.6 Bn in 2023
• It is expected to grow at a CAGR of 5.7% from 2024 to 2034 and reach US$ 74.8 Bn by the end of 2034

Inactivated Vaccines Market Overview

Attribute	Detail
Market Drivers	Rise in Incidence of Infectious Diseases Increasing Number of Clinical Research Activities

Regional Analysis

Attribute	Detail
Leading Region	North America

Inactivated Vaccines Market Snapshot

Attribute	Detail
Market Size in 2023	US$ 40.6 Bn
Market Forecast (Value) in 2034	US$ 74.8 Bn
Growth Rate (CAGR)	5.7%
Forecast Period	2024-2034
Historical Data Available for	2020-2022
Quantitative Units	US$ Bn for Value
Market Analysis	It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape	Market share analysis by company (2023) Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Market Segmentation	Vaccine Type Viral Vaccine Bacterial Vaccine Method of Inactivation Solvent Detergent Method Radiation Method pH Concentration Others (Heat Inactivation, etc.) Route of Administration Oral Subcutaneous Intravenous End-user Hospitals Specialty Clinics Homecare Settings Others (Research Centers, etc.)
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain China India Japan Australia & New Zealand Brazil Mexico South Africa GCC
Companies Profiled	GSK plc Novartis AG Mylan N.V. Sanofi S.A. Boehringer Ingelheim International GmbH Merck & Co., Inc. F. Hoffmann-La Roche AG Bristol-Myers Squibb Company Bharat Biotech Serum Institute of India INOVIO Pharmaceuticals, Inc.
Customization Scope	Available Upon Request
Pricing	Available Upon Request

The Vaccines Market report segments the industry into By Technology (Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, mRNA Vaccines, Recombinant Vaccines, Toxoid Vaccines, and more), By Type (Monovalent Vaccines, Multivalent Vaccines), By Disease Indication (DTP, Hepatitis, Herpes Zoster, HPV, Influenza, and more), By Route of Administration (Oral Administration, and more), By End-User, and By Geography.

Snapshot img

Human Combination Vaccines Market Size 2025-2029

The human combination vaccines market size is forecast to increase by USD 7.72 billion, at a CAGR of 8.8% between 2024 and 2029.

The market is characterized by significant growth opportunities and challenges. Key drivers include the increasing prevalence of infectious diseases and the growing awareness of the importance of vaccination in preventing them. However, the market also faces challenges, including the rising threat of antiviral drug resistance, which can reduce the effectiveness of some vaccines. Furthermore, the threat from bioterrorism has led to an increased focus on developing combination vaccines that can protect against multiple diseases simultaneously. Consolidation of different immunization schedules is another trend shaping the market, as healthcare providers seek to simplify vaccine administration and improve patient compliance. Companies in this market must navigate these challenges while capitalizing on the growing demand for combination vaccines to remain competitive and succeed. Effective strategies may include investing in research and development of new combination vaccines, expanding production capacity, and collaborating with healthcare providers to streamline immunization schedules. By addressing these challenges and leveraging market opportunities, companies can position themselves for long-term success in the market.

What will be the Size of the Human Combination Vaccines Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free SampleThe market continues to evolve, driven by the ongoing development of new technologies and applications across various sectors. Pneumococcal disease remains a significant focus, with research and innovation centered around pneumococcal conjugate vaccines, inactivated vaccines, and polysaccharide vaccines. The use of viral vectors, needle-free injection, and immunization programs is expanding, enhancing vaccine access and effectiveness. Market dynamics are shaped by factors such as regulatory approvals, cold chain management, and immunization schedules. Pharmaceutical companies are investing in peptide vaccines, t-cell response, and DNA vaccines, aiming to improve vaccine efficacy and healthcare costs. Market access remains a critical concern, with efforts to address vaccine hesitancy and ensure equitable distribution. The manufacturing process, quality control, and vaccine shelf life are essential considerations, with ongoing research into vaccine delivery systems, recombinant vaccines, and MRNA technology. Health outcomes and healthcare costs are under constant scrutiny, with global health initiatives and vaccination rates playing a crucial role in disease prevention and pandemic preparedness. Vaccine development pipelines are continually evolving, with clinical trials exploring the potential of new adjuvants, vaccine adjuvants, and vaccine effectiveness. The role of intellectual property, disease surveillance, and antibody response in shaping the market landscape is an ongoing discussion. The market's continuous dynamism underscores the importance of staying informed about the latest trends and developments.

How is this Human Combination Vaccines Industry segmented?

The human combination vaccines industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments. TypeInactivated vaccineLive attenuated vaccineChannelHospitalsRetailersOnlineRoute Of AdministrationIntramuscularSubcutaneousOralIntradermalNasal sprayGeographyNorth AmericaUSCanadaMexicoEuropeFranceGermanyItalyUKAPACChinaIndiaJapanRest of World (ROW)

By Type Insights

The inactivated vaccine segment is estimated to witness significant growth during the forecast period.The market encompasses a range of vaccine types, including inactivated, live-attenuated, subunit, conjugate, recombinant, peptide, and DNA vaccines. Inactivated vaccines, which account for the largest market share, utilize a process where pathogen particles are destroyed or killed, ensuring they cannot replicate. This segment's dominance is attributed to their better tolerability and fewer complications when combining different antigens. However, producing combination vaccines poses challenges due to potential incompatibilities and interactions among various components. Public awareness campaigns and regulatory approvals play a crucial role in driving the market, with a focus on pandemic preparedness and disease prevention. Vaccine packaging, cold chain management, and storage and stability are essential considerations to maintain vaccine efficacy. Clinical trials, vaccine delivery systems, and quality control are in

Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form (Liquid, Lyophilized) Type (Live Attenuated, mRNA, Inactivated), Route of Administration (Intramuscular, Subcutaneous, Oral), Approach, Indication, Packaging – Global Forecast to 2032

Vaccines Market size was valued at USD 82.96 Billion in 2024 and is projected to cross USD 174.79 Billion by the end of 2037, expanding at more than 5.9% CAGR during the forecast period i.e., between 2025-2037. The North America industry is anticipated to dominate, garnering a 38.6% share globally.

The global vaccine market was valued at USD 68.07 Billion in 2024. The industry is expected to grow at a CAGR of 10.50% during the forecast period of 2025-2034 to attain a valuation of USD 184.75 Billion by 2034.

The varicella vaccines market is estimated to reach USD 3,258.6 million in 2024. It is estimated that revenue will increase at a CAGR of 2.4% between 2024 and 2034. The market is anticipated to reach USD 4,115.4 million by 2034.

Attributes	Key Insights
Historical Size, 2023	USD 3,183.4 million
Estimated Size, 2024	USD 3,258.6 million
Projected Size, 2034	USD 4,115.4 million
Value-based CAGR (2024 to 2034)	2.4%

Semi Annual Market Update

Particular	Value CAGR
H1	3.4% (2023 to 2033)
H2	3.0% (2023 to 2033)
H1	2.4% (2024 to 2034)
H2	2.1% (2024 to 2034)

Country-wise Insights

Countries	Value CAGR (2024 to 2034)
Canada	1.3%
Germany	1.6%
France	1.5%
Italy	1.3%
China	2.8%
India	2.5%
Japan	1.7%

Category-wise Insights

Application	Monovalent Varicella
Value Share (2024)	67.2%

Capacity	Chickenpox Immunization
Value Share (2024)	39.6%

The Veterinary Vaccines Market Report is Segmented by Vaccine Type (Livestock Vaccines and Companion Animal Vaccines), Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Other Technologies), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The Market Size and Forecasts are Provided in Terms of Value (USD) for the Above Segments.

Global Swine Vaccines Market was valued at USD 1.32 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.85% through 2030.

Pages	180
Market Size	2024: USD 1.32 Billion
Forecast Market Size	2030: USD 1.74 Billion
CAGR	2025-2030: 4.85%
Fastest Growing Segment	Recombinant Vaccines
Largest Market	Asia Pacific
Key Players	1. Merck & Co Inc 2. Zoetis Inc 3. Boehringer Ingelheim GmbH 4. Elanco Animal Health Inc 5. Indian Immunologicals Ltd 6. Biogénesis Bagó SA 7. Phibro Animal Health Corp 8. Laboratorios HIPRA SA 9. Virbac SA